Ovarian cancer is not a single disease, but rather a group of diseases classified by type and subtype. And while they all affect the ovaries, they are quite unique in terms of origin and prognosis. High-grade serous ovarian cancer (HGSOC) is the most common subtype, accounting for the majority of diagnoses, and typically involving a first-line … Continued
Audra Moran, President & CEO of OCRA, joined Katie Couric to explain important new developments around symptoms and early detection of ovarian cancer, and what this means for the future. “A seminal study came out about a year and a half ago that showed, unfortunately, that early detection of ovarian cancer, even in an earlier … Continued
OCRA is pleased to award $7 million in ovarian cancer research funding for 2023, representing the largest annual research investment in our history. With this funding, 20 cancer researchers at 15 medical institutions across the country will pursue projects that break new ground in the fight against this disease. Selected by OCRA’s Scientific Advisory Committee for their potential … Continued
OCRA’s President & CEO, Audra Moran, spoke with CBS New York about the newest ovarian cancer risk and prevention updates, in an important segment timed to Ovarian Cancer Awareness Month.
An article published on February 2nd in The Washington Post highlights a turning point in our fight against ovarian cancer. As covered in the article, “Fallopian tube removal advised for more women to prevent ovarian cancer,” OCRA released a consensus statement, endorsed by the Society of Gynecologic Oncology, encouraging an aggressive prevention strategy: removal of the fallopian … Continued
An article published on February 1st in The New York Times highlights a turning point in our fight against ovarian cancer. As covered in the article, “To Prevent Cancer, More Women Should Consider Removing Fallopian Tubes, Experts Say,” OCRA is launching an important campaign centered around two messages with proven outcomes: knowing one’s risk, and … Continued
Today marks a turning point in our fight against ovarian cancer. As covered in The New York Times, we are launching an important campaign centered around two messages with proven outcomes: knowing one’s risk, and taking preventative action. You know better than anyone the challenges we face in the fight against ovarian cancer. There’s no … Continued
[NEW YORK, Feb. 1, 2023] — In a dramatic shift of focus in the fight against ovarian cancer, Ovarian Cancer Research Alliance (OCRA), the world’s leading ovarian cancer organization, today announced they will begin a nationwide push for genetic testing of those at increased risk and consideration of a prophylactic surgery even for those at average risk to potentially … Continued
Finding a method of early detection for ovarian cancer has been a primary focus of research for years, and was believed to be a promising approach to stopping women, or anyone born with ovaries, from dying of the disease. Some other cancers have demonstrated that earlier stage diagnoses can lead to better prognoses, and an oft-cited … Continued
OCRA is pleased to award research prizes to Dr. Ursula Matulonis and Dr. Pradeep Chaluvally-Raghavan, two investigators doing groundbreaking and important work in the field of ovarian cancer research. OCRA’s research prize recipients are selected by members of OCRA’s Scientific Advisory Committee. These prizes were awarded in December 2022. Dr. Ursula Matulonis Awarded Rosalind Franklin … Continued
Many people talk about New Year’s resolutions in the month of January, which is all well and good. But sometimes these long-range goals don’t exactly stick. Why not focus on simple actions you can take right now? Here are three things you can do in 2023 that will have a huge impact on OCRA, and … Continued
A recent study, funded in part by OCRA, has shed new light on how the most common subtype of ovarian cancer develops and metastasizes, by identifying a key molecule that allows malignancies in the fallopian tube to migrate to the ovaries and continue to grow. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype … Continued
Get email updates about research news, action alerts, and ways to join the fight.
